DIAGNOS - CEO, André Larente
CEO, André Larente
Source: La Presse
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC)
  • The CTMC will use the company’s AI engine CARA to begin screening Colombia’s population for eye-related issues
  • CARA (Computer Assisted Retina Analysis) integrates with existing equipment, and makes standard retinal images sharper, clearer, and easier to read
  • The two parties plan to begin the screening project in two major regions of Colombia in the following weeks
  • Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share 

Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC).

The CTMC has chosen DIAGNOS and its artificial intelligence engine, CARA, for a screening project. In alliance with the country’s largest specialist centre, the CTMC will use CARA to screen Colombia’s population for eye-related issues.

The CTMC’s founder, Dr Jorge Alberto Velez B, said this will unburden the heavy costs of blindness caused by diabetes.

CARA (Computer Assisted Retina Analysis) is a tele-ophthalmology platform that integrates with pre-existing hardware or software. The tool’s image enhancement algorithms make standard images of a person’s retina sharper, clearer, and easier to read. 

CARA can process results at the point of care, which will empower local technicians. However, specialists will validate the automated results before scheduling follow-ups with patients requiring further treatment.  

The CTMC and DIAGNOS plan to start the screening project in two major regions of Colombia, in the coming weeks.

DIAGNOS’ President, André Larente, commented on the service agreement with Colombia’s Telemedicine Centre. 

“We would like to thank the CTMC for choosing our CARA platform. We believe that CARA is a perfect fit as the main engine of the telemedicine solution.

“After a successful eye screening program with Bayer in 2015, we return to Colombia to engage our AI service into a practical solution for the local community. Along with CTMC, we can add value by making our unique service accessible,” he said. 

Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share.

More From The Market Herald

Optimi Health completes psilocybin extract validation

Optimi Health (CSE:OPTI) has reached a significant milestone, the successful harvest of eight new natural psilocybin genetics.

This stock is ready to capture the lead in the diabetes market

Diabetes specialist Glucotrack (NASDAQ:GCTK) has changed its business strategy to transition to continuous glucose monitoring.

Ceapro starts studies of flagship product for inflammation

Ceapro (TSXV:CZO) has launched a Phase 1 study evaluating its flagship product avenanthramides in managing inflammation-related conditions.